Genitourinary Cancer
BRCA mutations linked to increased risk for pancreatic, male breast, other cancers
Pathogenic variants in BRCA1 and BRCA2 appeared associated with increased risks for prostate cancer, pancreatic cancer, male breast cancer and possibly stomach cancer, according to research published in Journal of Clinical Oncology.
American Cancer Society CEO delivers call to action on genitourinary cancer disparities
SAN FRANCISCO — Addressing disparities in genitourinary cancers requires more research on changing risk factors and immediate actions aimed at prevention, Karen E. Knudsen, PhD, MBA, said during ASCO Genitourinary Cancers Symposium.
Immunotherapy benefits older patients with cancer, but closer monitoring may be warranted
Older patients with cancer benefited from single-agent immune checkpoint inhibitors but had higher rates of adverse events and therapy discontinuation with increasing age, according to results of a retrospective study in JAMA Oncology.
Trial-ineligible patients more likely to receive immunotherapy despite lack of benefit
Trial-ineligible patients with advanced cancer appeared nearly twice as likely as trial-eligible patients to receive immunotherapy, despite no evidence of a survival benefit compared with chemotherapy for this population.
PSA testing rates rose after USPSTF revised prostate cancer screening guideline
PSA testing rates increased after the U.S. Preventive Services Task Force revised its guidance on prostate cancer screening in 2017, according to results of a large national cohort study in JAMA Oncology.
Serial radiation therapy safe, effective for oligometastatic kidney cancer
Sequential radiotherapy to defer systemic therapy appeared to be a feasible strategy with encouraging PFS and OS among select patients with oligometastatic renal cell carcinoma, according to a study published in The Lancet Oncology.
Cabozantinib active, safe for brain metastases in patients with renal cell carcinoma
Cabozantinib demonstrated intracranial activity and appeared safe among patients with renal cell carcinoma and brain metastases, according to a study in JAMA Oncology.
FDA approves Keytruda for adjuvant treatment of renal cell carcinoma
The FDA expanded the approval of pembrolizumab to include adjuvant treatment of certain patients with renal cell carcinoma.
Immunotherapy combination confers durable benefit in advanced renal cell carcinoma
First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.
Tivozanib improves disease control in advanced renal cell carcinoma
Tivozanib induced a significantly higher disease control rate than sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.